• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:09:55 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    8-K
    false000153496900015349692025-05-072025-05-07

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 07, 2025

     

     

    Sera Prognostics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40606

    26-1911522

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2749 East Parleys Way

    Suite 200

     

    Salt Lake City, Utah

     

    84109

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (801) 990-0520

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A Common Stock, $0.0001 par value per share

     

    SERA

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 7, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except to the extent required by applicable law or regulation or as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit Number

     

    Description

    99.1

     

    Press release dated May 7, 2025.

     

     

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SERA PROGNOSTICS, INC.

     

     

     

     

    Date:

    May 7, 2025

    By:

    /s/ Austin Aerts

     

     

     

    Austin Aerts
    Chief Financial Officer

     


    Get the next $SERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    SEC Filings

    See more
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:20:09 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:19:32 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/8/25 5:20:29 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/14/24 5:46:12 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/4/24 7:19:49 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Sera Prognostics Inc.

      SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      4/1/24 7:33:43 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

      SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

      5/15/23 5:15:00 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mirza Mansoor Raza sold $259 worth of shares (106 units at $2.44), decreasing direct ownership by 0.24% to 43,672 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:31 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Executive Officer Lindgardt Zhenya sold $22,951 worth of shares (9,406 units at $2.44), decreasing direct ownership by 1% to 867,251 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:14 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Data Officer Kearney Paul sold $17,297 worth of shares (7,089 units at $2.44), decreasing direct ownership by 3% to 196,711 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:53 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sera Prognostics downgraded by Citigroup with a new price target

      Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

      3/30/22 7:52:32 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Oppenheimer initiated coverage on Sera Prognostics with a new price target

      Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

      11/19/21 4:55:47 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Sera Prognostics

      Cowen resumed coverage of Sera Prognostics with a rating of Outperform

      10/15/21 7:31:16 AM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Financials

    Live finance-specific insights

    See more
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR

      3/19/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care